Leech C1 Inhibitor (LCi)
Complement system modulator targeting C1q activation — immunological homeostasis.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Complement system modulator targeting C1q activation — immunological homeostasis.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
Clinical translation limit
Leech C1 inhibitor's reported complement-pathway modulation is preclinical/biochemical only. Not to be confused with the FDA-approved human C1-esterase inhibitor concentrates used in hereditary angioedema — those are unrelated human-plasma products. No leech-derived C1-inhibitor is FDA-approved.
Molecular Profile
- Category
- Anti-inflammatory
- Evidence tier
- Preclinical
- Molecular weight
- 30,000 Da
- Source species
- Hirudo medicinalis
Biological Targets
- → complement C1q, classical pathway
Key Citations
- Baskova IP, Zavalova LL (2001), Biochemistry (Mosc) · PMID 11563948
External Resources
Related Anti-inflammatory Compounds
Leech Eicosanoid Modulator
Modulates prostaglandin and leukotriene cascades — anti-inflammatory pathway.
Leech Phospholipase A2 Inhibitor
Putative PLA2 inhibitor identified in leech salivary transcriptome — candidate eicosanoid-cascade modulator.
Haemadipsa yanyuanensis Progranulin (Hy-PGRN)
Putative progranulin gene with 122 cysteine residues and nine tandem repeats — distinctive structural organization (Lin 2025 chromosome-level genome).
WP-EAGSAKELEGDPVAG
Whitmania pigra-derived 15-residue anti-atherosclerosis peptide — Hu 2020 demonstrates inhibition of macrophage migration via JNK + p38 MAPK pathways.